Search results
Nov 16, 2023 · The deal is expected to close before this year’s end. Upon closing, Arcellx will receive a $200-million equity investment from Gilead, after which the latter will own a 13% stake in the former.
Nov 15, 2023 · Upon closing, Arcellx will receive a $200 million equity investment to purchase 3,242,542 shares of its common stock, which is expected to extend the company's cash runway into 2027. Following ...
People also ask
What happened to arcellx aclx?
How much money will arcellx receive at closing?
Will arcellx be able to expand its cash runway in 2027?
Are arcellx & kite collaborating?
Nov 15, 2023 · SANTA MONICA, Calif. & REDWOOD CITY, Calif.-- (BUSINESS WIRE)-- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced that the companies have expanded their existing collaboration, which was originally announced in December 2022. Kite has exercised its option to negotiate a license for Arcellx’s ARC-SparX ...
Dec 9, 2022 · The transaction is expected to close in the first quarter of 2023. Closing of the transaction is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.
Jan 30, 2023 · SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the ...
Dec 9, 2022 · The deal is expected to close in the first quarter of 2023. Arcellx raises $124M in Wall Street debut to bankroll study of multiple myeloma CAR-T.
Dec 12, 2022 · The transaction is expected to close in the first quarter of 2023. Kite will commercialize the product and Arcellx will receive royalties on sales outside the US.
